Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/c9/9e/be/c99ebe14-01ae-3f05-8f3e-0a411ec9d5f8/mza_5376284641823889153.jpg/600x600bb.jpg
JNM Podcast
JNM
15 episodes
1 month ago
Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...
Show more...
Medicine
Health & Fitness
RSS
All content for JNM Podcast is the property of JNM and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...
Show more...
Medicine
Health & Fitness
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/c9/9e/be/c99ebe14-01ae-3f05-8f3e-0a411ec9d5f8/mza_5376284641823889153.jpg/600x600bb.jpg
From Isotope to Impact: 211At
JNM Podcast
28 minutes
2 months ago
From Isotope to Impact: 211At
Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, M...
JNM Podcast
Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...